We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New H&E Tissue Staining Solution Sets New Standard in Histopathology

By LabMedica International staff writers
Posted on 07 Dec 2015
Print article
A new hematoxylin and eosin (H&E) staining system provides exceptionally high tissue staining quality and efficiency that enhances patient care as well as lab technician safety.

The new “VENTANA HE 600” staining system from Roche (Basel, Switzerland) delivers fresh reagents on each individual slide without relying on user-supplied alcohol and deionized (DI) water, resulting in improved consistency and quality. This individual slide staining technology mitigates the risk of specimen cross-contamination that can occur with other technologies, helping to reduce patient misdiagnosis.

Elimination of xylene and alcohol and utilization of ready-to-use reagents reduce technician exposure to harmful chemicals. Workflow is improved by eliminating the need to manually mix reagents and track product expiration dates. The system offers over 400 individual staining protocols and is highly customizable, allowing for laboratory and pathologist preferences and tissue variables.

In a recent global test, over 4,000 slides from laboratories in 12 countries were stained on VENTANA HE 600 and reviewed by 67 pathologists with excellent results. Evaluation of the criteria, including nuclear detail and stain quality and intensity, resulted in a score of 3.7 on a scale of 4.0.

Robert C. Babkowski, MD, the lead pathologist on a recent 4-week beta-test conducted at Stamford Hospital where he reviewed over 1,000 slides, said, “When we compared our current system, the VENTANA HE 600 system is easier to use, the slides are exquisite, and the consistency is solid. The new system provides beautifully stained slides every time and has allowed me, as a working pathologist, to be even more efficient. Because the instrument is so easy to operate, my histo-technologists are now able to focus on other key histology functions.” Stamford Hospital is one of 4 beta-test sites.

“Approximately 80% of a pathologist's diagnostic report comes from the H&E stain. The VENTANA HE 600 system will help change the standard of care for laboratories, pathologists and, most importantly, cancer patients, who rely heavily on the H&E test,” said Roland Diggelmann, COO, Roche Diagnostics Division, “The system reflects Roche’s commitment to delivering innovation that meets the labs’ needs of today and tomorrow through meaningful advancements in staining quality, patient and laboratory safety, and workflow.”

Related Links:

Roche


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bead-Based Multiplex Assay
Human Luminex Discovery Assay
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.